| ID | 1023 |
| Name of the vaccine | Actacel |
| Microbe | Bacteria |
| Disease name | Diphtheria |
| Name of bacteria | Corynebacterium diphtheriae |
| Type of vaccine | Subunit |
| Nucleic acid content | DNA |
| Age | 2 months to 6 years |
| Description of the vaccine | Act-HIB reconstituted with Tripacel is Diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b conjugate vaccine. |
| Name of the manufacturer | Sanofi Pasteur Ltd |
| Name of the manufacturing country | Canada |
| Year of manufacture | 2001 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive bacillus. |
| Efficacy | NA |
| Vaccine formulation | White to off-white suspension |
| Dosage | Three dose immunization series, interval of 2 months, followed by a fourth dose. |
| Mechanism of action | NA |
| Route of administration | Intramuscular |
| Indications | Immunization against diphtheria, tetanus and pertussis and invasive Haemophilus influenzae type b infections. |
| Export | Marketing Authorisation Holder: Sanofi Pasteur Ltd, Bangkok, Thailand |
| Approval | NA |
| Adjuvant | Aluminium phosphate |
| Repurposing | For pertussis, Hib and tetanus. |
| Side effects of vaccine | Injection site tenderness, swelling, redness, fever, fussiness, irritability, less active, eating less, crying, diarrhoea. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | http://www.violinet.org/vaxquery/vaccine_detail.php?c_vaccine_id=761 |
| Other name | NA |
| Additional Links | https://www.fda.moph.go.th/sites/drug/Summary/2C_25_44_N.pdf
|